Hybio Pharmaceutical Co., Ltd. (SHE:300199)

Market Cap	19.52B +54.7%
Revenue (ttm)	955.53M +27.4%
Net Income	94.52M
EPS	0.10
Shares Out	883.24M
PE Ratio	216.09
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,603,284
Open	21.86
Previous Close	19.77
Day's Range	18.90 - 22.28
52-Week Range	15.88 - 31.19
Beta	0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermedia...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 1,226
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300199

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 29, 2026

Data Sources Report a data error